PER 1.27% 7.8¢ percheron therapeutics limited

Ann: US FDA Grants RPDD to ATL1102 for the treatment of DMD, page-94

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 84 Posts.
    lightbulb Created with Sketch. 42
    Okay you clearly haven't spent time working in healthcare because no doctor spends 5 hours on a patient every week, the protocol won't require it in any case.

    The direct cost of managing a patient with duchenne is close to 20k/year, including medications, hospital visits, clinic visits

    https://pubmed.ncbi.nlm.nih.gov/28530521/
    When you're thinking about clinical trials, all that's required on top of that is probably a fortnightly blood test, weekly drug injection, and those PUL2 assessments maybe every month, a few MRI scans, and questionnaires. Clinic visits will be more frequent, say once a month, but your costs won't blow out to 150k per patient.
    I cant see how adding a few more scans, blood tests, and clinic visits will cost more than double their routine medical costs inclusive of medications.

    40k * 75 = 3m USD = 4.5m AUD is a reasonable estimate. Easily achievable with a small cap raise or exercise of options.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
7.8¢
Change
-0.001(1.27%)
Mkt cap ! $79.83M
Open High Low Value Volume
8.0¢ 8.0¢ 7.7¢ $374.4K 4.803M

Buyers (Bids)

No. Vol. Price($)
3 308385 7.8¢
 

Sellers (Offers)

Price($) Vol. No.
8.0¢ 818650 4
View Market Depth
Last trade - 16.10pm 04/11/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.